{"name":"Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.","slug":"innovent-biopharmaceutical-technology-hangzhou-co-ltd","ticker":"","exchange":"","domain":"innoventbiopharmaceuticaltechnologyhangzhou.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"IBI3020","genericName":"IBI3020","slug":"ibi3020","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"IBI112","genericName":"IBI112","slug":"ibi112","indication":"Non-small cell lung cancer","status":"phase_3"}]}],"pipeline":[{"name":"IBI3020","genericName":"IBI3020","slug":"ibi3020","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IBI112","genericName":"IBI112","slug":"ibi112","phase":"phase_3","mechanism":"IBI112 is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Gastric cancer","Other solid tumors (in development)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOSjZPQ3dCVnViR3JRdDVfcFZXbE1oZmRCSk1qaWF5ZkZ6SjRjNHh5V0RuemtXeUY1ZmIzRjhqUkI1dnZyNFd1Sy1veGF0S0dRaHU0SG92RFBMZmMxUXRhemJFN1Q4X0J4VnlMWDhCa3FibG9XTE84MTJGZzBZb3NXMWI5NkIyOUF1QWtyUkItNVdGQQ?oc=5","date":"2024-09-12","type":"pipeline","source":"BioWorld News","summary":"China biotechs rise to challenge Ozempic, Wegovy - BioWorld News","headline":"China biotechs rise to challenge Ozempic, Wegovy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQc2VNLU4zWlFJUXBPRTJEd0sydWNPTUx5OUFzTVFYNXR5MnZPZTF2Qkc2dFBjLVFmb01RTDVEOE9VN3hsaXJKX1g4b3JyTV83eEpnRnAtNTNHemZSWFQwaUswbGdWd3ZRMWdsMkVZalpWalJXdkl3aWktSGRKcW5OSVZBNjlvN09scjlqN3dQVmtaSmQ4bWw3ZkJvRGxOdVR1bVNFZ3FYYjMwYUFQZURrMXd2eXdRV0tyZjRMTmNtUE1sOXc?oc=5","date":"2018-07-20","type":"pipeline","source":"Caixin Global","summary":"Ascletis Is First Biotech Firm With IPO in Hong Kong After Rules Eased - Caixin Global","headline":"Ascletis Is First Biotech Firm With IPO in Hong Kong After Rules Eased","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":1,"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}